NUTM1 and nut midline carcinoma: Among the BET inhibitors, Birabresib (OTX015/MK-8628) showed efficacy in patients affected by NUT midline carcinoma (NMC) harboring the BRD4–NUT fusion oncoprotein, providing the first proof-of-concept evidence of clinical activity of a BRD inhibitor in targeting BRD4–NUT; three out of ten patients (30%) with NMC had a partial response (PR) with duration of response (DOR) of 1.4 to 8.4 months [8].